Ghrelin Receptor (GHS-R1a)

Overview

GHS-R1a (growth hormone secretagogue receptor type 1a) was discovered pharmacologically before its endogenous ligand. Synthetic hexapeptides, the precursors to modern GHRPs, were found in the late 1970s and 1980s to stimulate GH secretion through an unknown receptor distinct from the GHRH receptor. The receptor was eventually cloned in 1996, and the endogenous ligand, ghrelin, was discovered three years later by Kojima et al. in 1999 using a reverse pharmacology approach that screened stomach extracts for compounds able to activate the orphan receptor.

GHS-R1a is a seven-transmembrane G protein-coupled receptor (GPCR) belonging to the class A (rhodopsin-like) family. It is expressed in multiple tissues, most importantly in the anterior pituitary somatotrophs (where its activation drives GH secretion), the hypothalamic arcuate nucleus and other hypothalamic regions (where it mediates appetite and energy homeostasis), and also in peripheral tissues including the heart, pancreas, adrenal gland, and gastrointestinal tract. The receptor has constitutive (ligand-independent) activity, meaning it is partially active even in the absence of ghrelin, a property that is unusual among GPCRs and contributes to basal GH secretion and appetite regulation.

The receptor's dual role, in GH secretion and in appetite signalling, explains the principal off-target effect of most GHRPs: hunger stimulation. The degree of appetite stimulation varies substantially across synthetic ligands. GHRP-6 produces the most pronounced appetite effect of the commonly researched peptides; Ipamorelin is notable for selective GH release with minimal appetite co-stimulation, attributed to its structural selectivity within the GHS-R1a binding pocket.

How It Works

Tracing the pathway from GHS-R1a activation through to pulsatile GH release requires understanding the signalling cascade, the interplay with somatostatin and GHRH, and the downstream GH-IGF-1 axis effects.

Peptides Investigated in This Context

All five compounds share GHS-R1a as their primary mechanism. MK-677 is not a peptide (it is a small-molecule spiropiperidine) but is included because it acts on the same receptor as the GHRP peptide class and is commonly researched alongside peptide GH secretagogues.

Research Context

The growth hormone secretagogue receptor was identified through a long pharmacological investigation beginning with the synthesis of Met-enkephalin-derived hexapeptides in the late 1970s at Tulane University by Cyril Bowers and colleagues. These early compounds (precursors to GHRP-6) were found to stimulate GH secretion through a mechanism distinct from GHRH. Bowers continued the structural optimisation programme, eventually producing the compounds that became GHRP-2 and GHRP-6. Howard, Feighner, McKee, and colleagues at Merck cloned GHS-R1a in 1996 from porcine pituitary and hypothalamus tissue, revealing that an orphan GPCR was responsible for GHRP activity. In 1999, Kojima et al. at Kurume University identified ghrelin as the endogenous GHS-R1a ligand, completing the receptor-ligand picture.

Ipamorelin was described in 1998 by Raun et al. at Novo Nordisk and represented a structural refinement that achieved selectivity for GH over cortisol and prolactin. MK-677 (Ibutamoren) was developed by Merck as an oral GH secretagogue and advanced to Phase 2 clinical trials for sarcopenia, growth hormone deficiency, and cachexia, with Phase 2 data demonstrating sustained IGF-1 elevation at daily doses of 10 to 25 mg. Despite its clinical trial history, MK-677 has not received regulatory approval for any indication; the Phase 3 programme for frailty was discontinued. Hexarelin was investigated clinically and found to maintain GH-stimulating activity in patients with GH deficiency who did not respond to GHRH, consistent with its receptor acting downstream (at the pituitary level) of the hypothalamic GHRH input.

Related Mechanisms